Outcomes of Thoracentesis for Acute Heart Failure in Hospitals
Heart failure (HF) is the most common cause of transudative pleural effusion and the second most common cause of pleural effusion overall 1-3. The incidence of pleural effusion in acute HF is estimated at 46% based on the plain radiographic diagnosis. Its incidence may reach as high as 85-90% when using a more sensitive diagnostic modality such as ultrasound or computerized tomography scan 1,4. Thoracentesis (THR) is widely utilized to improve symptoms of patients with HF 5. However, the actual prognostic value of THR in HF has been sparsely reported with only one study reporting a 22% mortality rate at 30-days and 53% at 1 year, which is significantly higher than the known average mortality rate for HF 6.
Sometimes when the discussion of tackling the novel coronavirus comes up, the use of medical devices gets lost in the shuffle. Most of the conversation surrounding COVID-19 comes from either the promise of a vaccine or the expansion of tests. Abiomed is adding to the conversation surrounding medtechâs potential contribution to the treatment of COVID-19 patients. Monday, the Danvers, MA-based company by receiving Emergency Use Authorization for a device to treat COVID-19 related right heart failure patients. The Impella RP is a temporary heart pump that provides circulatory support for patients who develop...
Resumo A doen ça de coronavírus 2019 (COVID-19) é uma pandemia global afetando o mundo, estando presente em mais de 1.300.000 pacientes. O COVID-19 age pelo receptor da enzima conversora de angiotensina 2 (ECA2). As comorbidades cardiovasculares são mais frequentes com COVID-19, e cerca 10% de casos desenvolv em miocardite (22% de pacientes críticas). Mais pesquisas serão necessárias para continuar ou descontinuar inibidores de ECA e bloqueadores dos receptores da angiotensina, que são essenciais para hipertensão e insuficiência cardíaca em COVID-1...
The authorization allows use of the temporary heart pump in the treatment of right heart failure or decompensation, including pulmonary embolism, caused by COVID-19 complications.FDA Approvals
Publication date: Available online 31 May 2020Source: Revista Clínica Española (English Edition)Author(s): A. González-Franco, L. Manzano
by Stephen P. Wood, MS, ACNP-BC I stood facing the iPad attached to a rolling stand punching in the phone number of the young granddaughter of my intensive care unit patient. He arrived less than twenty-four hours before. I had taken the call the day before from the outside hospital emergency department and the story was grim. This was a seventy-six-year-old male who had acute myeloid leukemia, hypertension, as well as a history of congestive heart failure. He had been sick for the past two days with a fever, a cough and weakness.…
This article will explain the pathophysiology and benefits of exercise in those with the condition, as well as provide recommendations for home-based training for individuals with CHF.
To evaluate associations of high-sensitivity cardiac troponin-T (cTnT) with cardiovascular disease (CVD), heart failure (HF), and mortality in community-dwelling women and men.
Cardiovascular comorbidities and risk reduction play a major new role in pharmacologic therapy for type 2 diabetes, with sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists now recommended as part of the glucose-lowering regimen for patients who have established atherosclerotic cardiovascular disease (ASCVD) or indicators of high-risk, chronic kidney disease (CKD) or heart failure (HF).
Publication date: August 2020Source: IJC Heart &Vasculature, Volume 29Author(s): Inder Anand, Jeffrey L. Ardell, Doug Gregory, Imad Libbus, Lorenzo DiCarlo, Rajendra K. Premchand, Kamal Sharma, Sanjay Mittal, Rufino Monteiro
Authors: Tzikas S, Papadopoulos C, Evangeliou AP, Vassilikos V PMID: 32470561 [PubMed - as supplied by publisher]